As part of its strategy for preventing bacterial illnesses similar to those found in Abbott Laboratories’ products, the U.S. regulator for health said Tuesday that it will review guidelines and rules regarding infant formula manufacturing.
It said that the Food and Drug Administration will consider whether to create a dedicated team of investigators and realign employees across two divisions in order to support regulatory oversight of infant formulations.
BABY FORMULA SMALLAGE IS A BIG PROBLEM FOR OHIO FAMILY WITH 4 MONTH-OLD INFANT
Following complaints about infection by cronobacter, the FDA issued this statement.
The sign was seen outside the White Oak headquarters of Food and Drug Administration (FDA), Maryland, U.S.A, on August 29, 2020. (Reuters/Andrew Kelly/File Photo)
The shutdown of the plant and the recalls of Abbott infant formula products exacerbated a shortage, sending parents in the United States scrambling. In July, Abbott’s plant was reopened.
CLICK HERE TO GET FOX NEWS APP
Although the infection is rare in most states and not reported in many, it can cause serious complications in newborns. Following reports of four cases, and two deaths, Abbott products were recalled.
